



## Tilray® Expands Global Leadership Team with Appointment of Chief Corporate Development Officer

Mar 13, 2019

***Former Goldman Sachs Managing Director Andrew Pucher joins Tilray to lead the company's global corporate development activity, including M&A and corporate investments***

NANAIMO, British Columbia--(BUSINESS WIRE)--Mar. 13, 2019-- Today, Tilray, Inc. (NASDAQ:TLRY), a global pioneer in cannabis production, research, cultivation and distribution, announces the expansion of its global senior leadership team with the appointment of Andrew Pucher as Chief Corporate Development Officer. In his new role, Andrew will lead Tilray's corporate development function, including the team that is responsible for M&A and corporate investments. He will be based in Toronto, ON, and report to CEO Brendan Kennedy.

This press release features multimedia. View the full release here: <https://www.businesswire.com/news/home/20190313005090/en/>



Andrew Pucher, Chief Corporate Development Officer,  
Tilray (Photo: Business Wire)

Andrew joins Tilray from Goldman Sachs, where he was a Managing Director and most recently served as Head of Canadian Diversified Investment Banking, which included coverage of the Canadian cannabis industry. Previously, he was a member of Goldman Sachs' Global Healthcare Investment Banking Group in New York, where he advised on more than \$200 billion in announced M&A and financing transactions, with a focus on the biopharmaceutical sector. Andrew is a graduate of Simon Fraser University and earned a JD/MBA from York University.

Brendan Kennedy, Tilray's CEO, said, "We're pleased to welcome Andrew to our senior leadership team to execute strategic transactions that will further accelerate Tilray's long-term global growth. Andrew shares our commitment to a disciplined, strategic approach in pursuing inorganic growth opportunities. His transaction experience and industry knowledge will be valuable as we work to capitalize on the many strategic opportunities available to us and continue to pursue the disruptive potential of cannabis across industries including pharmaceuticals, alcohol, consumer goods, functional food and beverage, retail and nutraceuticals."

Recent Tilray transactions and partnerships include: forming a global partnership with Sandoz, a division of Novartis, to distribute its medical products; establishing a 50/50 joint venture with AB InBev, the world's largest brewer, to develop THC and CBD beverages; signing an agreement to produce THC and CBD products for Authentic Brands Group portfolio of brands, which includes Muhammed Ali, Nine West, Spyder ski gear, Prince tennis wear, Marilyn Monroe, Juicy Couture and Elvis Presley; acquiring Natura Naturals Holdings, thereby increasing its cannabis supply; and most recently, announcing the acquisition of Manitoba Harvest, the world's largest hemp company, accelerating the company's entry into the natural foods space with hemp and CBD-infused food and wellness products for North America.

Over the past several months, Tilray has announced appointments to its senior leadership team, with executives from world-leading brands: Sascha Mielcarek joined Tilray from Grünenthal to become Managing Director, Europe; Greg Christopher joined from Nestle to become Tilray's EVP of Operations; Rita Seguin came on board from Diageo to be Tilray's EVP of Human Resources; Dara Redler, Tilray's General Counsel worked previously at The Coca-Cola Company; and Charlie Cain as VP of Retail came from Starbucks Corporation.

### About Tilray®

Tilray (NASDAQ:TLRY) is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients and consumers in twelve countries spanning five continents.

### Cautionary Note Regarding Forward-looking Statements

*This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this press release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe", "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions and include statements relating to the growth and global success of the Tilray. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment and future approvals and permits. Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such forward-looking statements and they are not guarantees of future results. Forward-looking statements involve significant risks, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements. Please see the heading "Risk Factors" in Tilray's Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission and Canadian securities regulators on November 14, 2018, for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. Tilray does not undertake to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.*

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190313005090/en/>

Source: Tilray, Inc.

Media: Chrissy Roebuck, 1-833-206-8161, [news@tilray.com](mailto:news@tilray.com)  
Investors: Katie Turner, +1-646-277-1228, [Katie.turner@icrinc.com](mailto:Katie.turner@icrinc.com)